Planning Underway for Phase 3 Clinical Trial Testing Encapsulated Cell-Based Delivery of CNTF
Planning is underway for a Phase 3 clinical trial to test encapsulated cell-based delivery of Ciliary Neurotrophic Factor (CNTF) for the treatment of macular telangiectasia type 2. The decision to run a Phase 3 clinical trial follows the announcemen...
Results of NT-501 Phase 2 Study Published
January 16, 2019, Cumberland, RI and La Jolla, CA. The results of the NT-501 Phase 2 study sponsored by Neurotech Pharmaceuticals, Inc. (Neurotech) in collaboration with the Lowy Medical Research Institute (LMRI), have been published in the journal o...
Neurotech Announces Positive Phase 2 Results in NT-501 (CNTF) for Macular Telangiectasia
Neurotech Pharmaceuticals, Inc., in collaboration with the Lowy Medical Research Institute (LMRI), today announced 24-month results demonstrating that NT-501 delivering Ciliary Neurotrophic Factor (CNTF) has a beneficial effect in patients with Macul...
NHOR Newsletter Announcement
The Lowy Medical Research Institute would like to announce the latest MacTel Project Newsletter, which contains important updates on the Natural History Observation and Registry (NHOR) Study, Clinical Trials, and MacTel Projects.